穿戴式注射器市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

2024 年全球穿戴式注射器市場規模達 90 億美元，預計 2025 年至 2034 年複合年成長率為 12.3%。慢性病盛行率的不斷上升、技術的不斷進步以及對創新藥物輸送系統日益成長的需求正在推動市場成長。隨著醫療保健系統轉向以患者為中心的模式，穿戴式注射器正成為有效管理慢性病的重要工具。這些設備提供了一種無縫且便利的用藥方式，提高了患者的依從性和治療效果。

全球醫療保健產業正在經歷範式轉變，強調個人化醫療、家庭治療和數位醫療保健解決方案。隨著糖尿病、心血管疾病和自體免疫疾病等慢性疾病負擔的不斷增加，對高效且使用者友好的藥物傳遞系統的需求變得越來越重要。穿戴式注射器消除了頻繁去醫院的麻煩，使患者能夠精確地自行用藥。便利性、提高依從性和減少對醫療設施的依賴是推動廣泛採用的關鍵因素。此外，製藥公司正大力投資開發整合智慧技術的先進穿戴式注射器，進一步提升病患體驗。無線連接的整合實現了遠端監控，為醫療保健專業人員提供有關治療依從性和患者反應的即時資料。

市場主要分為兩類：離體注射器和體內注射器。 2023 年體內注射器市場規模將達 81 億美元，預計複合年成長率為 13.5%。這些設備使患者能夠獨立服用藥物，減少對護理人員的依賴並提高生活品質。需要長期治療慢性病的人數不斷增加，大大增加了對體內注射器的需求。它們能夠提供精確的劑量、減輕不適並增強治療依從性，使其成為患者和醫療保健提供者的首選。

根據注射輸送類型，穿戴式注射器市場進一步分為程序輸送和推注輸送。 2024 年程序化給藥領域的價值為 46 億美元，預計 2025 年至 2034 年期間的複合年成長率為 11.7%。程序化給藥系統經過專門設計，可確保長期準確給藥，是需要持續用藥的患者的理想選擇。這些系統減輕了傳統手動注射方法中劑量不足或過量的風險，改善了整體治療效果。人們對精準醫療和針對特定患者的藥物治療方案的日益關注，推動了程序化輸送穿戴式注射器的採用。

美國穿戴式注射器市場價值預計到 2024 年將達到 30 億美元，預計將大幅成長。糖尿病、肥胖症和關節炎等慢性疾病發病率的上升推動了對自我給藥系統的需求。穿戴式注射器中智慧技術的整合透過實現即時監控和遠端依從性追蹤徹底改變了患者護理。隨著醫療保健提供者優先考慮以患者為中心的解決方案，對智慧和互聯藥物輸送設備的需求持續上升。隨著製藥和醫療技術公司對尖端創新的投資，美國市場有望在塑造全球穿戴式注射器的未來方面發揮關鍵作用。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 慢性病發生率不斷上升
    • 轉向居家醫療保健
    • 生物製劑需求不斷成長
    • 患者對微創設備的偏好
    • 全球人口老化
  • 產業陷阱與挑戰
    • 穿戴式注射器成本高
    • 技術和設計挑戰
• 成長潛力分析
• 技術進步
• 監管格局
• 比較分析：患者對手持式自動注射器與穿戴式大容量注射器的偏好
• 波特的分析
• PESTEL分析
• 未來市場趨勢
• 差距分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按類型，2021 - 2034 年

• 主要趨勢
• 體內注射器
• 離體注射器

第6章：市場估計與預測：按設備類型，2021 - 2034 年

• 主要趨勢
• 可編程穿戴式注射器
• 不可編程穿戴式注射器

第7章：市場估計與預測：按注射輸送類型，2021 - 2034 年

• 主要趨勢
• 計劃交付
• 推注給藥

第8章：市場估計與預測：按使用類型，2021 - 2034 年

• 主要趨勢
• 免洗穿戴式注射器
• 可重複使用的穿戴式注射器

第9章：市場估計與預測：按技術，2021 - 2034 年

• 主要趨勢
• 基於 Spring
• 馬達驅動
• 擴充電池
• 旋轉泵
• 其他技術

第 10 章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 糖尿病
• 心血管疾病
• 腫瘤學
• 自體免疫疾病
• 傳染病
• 其他應用

第 11 章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 居家照護環境
• 醫院和診所
• 門診手術中心

第 12 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第13章：公司簡介

• Amgen
• Bayer
• Becton Dickinson (BD)
• CeQur
• Eli Lilly and Company
• Enable Injections
• Eoflow
• Gerresheimer
• Insulet
• Medtronic
• novo nordisk
• Roche
• TANDEM Diabetes Care
• Valeritas
• West
• Ypsomed Selfcare Solutions

The Global Wearable Injectors Market reached USD 9 billion in 2024 and is projected to witness a CAGR of 12.3% from 2025 to 2034. The increasing prevalence of chronic diseases, continuous technological advancements, and the rising demand for innovative drug delivery systems are fueling market growth. With healthcare systems shifting toward patient-centric models, wearable injectors are emerging as essential tools for managing chronic conditions efficiently. These devices offer a seamless and convenient way to administer medications, improving patient compliance and treatment efficacy.

The global healthcare industry is experiencing a paradigm shift, emphasizing personalized medicine, home-based treatments, and digital healthcare solutions. As the burden of chronic diseases such as diabetes, cardiovascular disorders, and autoimmune diseases continues to rise, the need for efficient and user-friendly drug delivery systems is becoming more critical. Wearable injectors eliminate the hassle of frequent hospital visits, allowing patients to self-administer medications with precision. Convenience, improved adherence, and reduced dependency on healthcare facilities are key factors driving widespread adoption. Additionally, pharmaceutical companies are heavily investing in the development of advanced wearable injectors with integrated smart technology, further enhancing the patient experience. The integration of wireless connectivity enables remote monitoring, providing healthcare professionals with real-time data on treatment adherence and patient response.

The market is segmented into two main categories: off-body injectors and on-body injectors. The on-body injectors segment accounted for USD 8.1 billion in 2023, with an expected CAGR of 13.5%. These devices empower patients to administer their medications independently, reducing reliance on caregivers and improving quality of life. The growing number of individuals requiring long-term treatment for chronic illnesses is significantly boosting demand for on-body injectors. Their ability to provide precise dosing, reduce discomfort, and enhance therapy adherence makes them a preferred choice for both patients and healthcare providers.

The wearable injectors market is further categorized based on injection delivery type into programmed delivery and bolus delivery. The programmed delivery segment was valued at USD 4.6 billion in 2024 and is anticipated to grow at a CAGR of 11.7% between 2025 and 2034. Programmed delivery systems are specifically designed to ensure accurate dosing over time, making them ideal for patients requiring continuous medication administration. These systems mitigate the risks of underdosing or overdosing associated with traditional manual injection methods, improving overall treatment outcomes. The increasing focus on precision medicine and patient-specific drug regimens is propelling the adoption of programmed delivery wearable injectors.

The U.S. wearable injectors market, valued at USD 3 billion in 2024, is poised for substantial growth. The rising incidence of chronic diseases such as diabetes, obesity, and arthritis is driving demand for self-administration drug delivery systems. The integration of smart technologies in wearable injectors is revolutionizing patient care by enabling real-time monitoring and remote adherence tracking. As healthcare providers prioritize patient-centric solutions, the demand for intelligent and connected drug delivery devices continues to rise. With pharmaceutical and medtech companies investing in cutting-edge innovations, the U.S. market is expected to play a pivotal role in shaping the future of wearable injectors on a global scale.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of chronic conditions
    • 3.2.1.2 Shift towards home-based healthcare
    • 3.2.1.3 Increasing demand for biologics
    • 3.2.1.4 Patient preference for minimally invasive devices
    • 3.2.1.5 Global aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of wearable injectors
    • 3.2.2.2 Technical and design challenges
• 3.3 Growth potential analysis
• 3.4 Technological advancements
• 3.5 Regulatory landscape
• 3.6 Comparative analysis: patient preferences for handheld autoinjectors Vs wearable large-volume injectors
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 On-body injectors
• 5.3 Off-body injectors

Chapter 6 Market Estimates and Forecast, By Device Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Programmable wearable injectors
• 6.3 Non-programmable wearable injectors

Chapter 7 Market Estimates and Forecast, By Injection Delivery Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Programmed delivery
• 7.3 Bolus delivery

Chapter 8 Market Estimates and Forecast, By Usage Type, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Disposable wearable injectors
• 8.3 Reusable wearable injectors

Chapter 9 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Spring-based
• 9.3 Motor-driven
• 9.4 Expanding battery
• 9.5 Rotary pump
• 9.6 Other technologies

Chapter 10 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Diabetes
• 10.3 Cardiovascular disease
• 10.4 Oncology
• 10.5 Autoimmune disease
• 10.6 Infectious disease
• 10.7 Other applications

Chapter 11 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 Home care settings
• 11.3 Hospitals and clinics
• 11.4 Ambulatory surgical centers

Chapter 12 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 Japan
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 Amgen
• 13.2 Bayer
• 13.3 Becton Dickinson (BD)
• 13.4 CeQur
• 13.5 Eli Lilly and Company
• 13.6 Enable Injections
• 13.7 Eoflow
• 13.8 Gerresheimer
• 13.9 Insulet
• 13.10 Medtronic
• 13.11 novo nordisk
• 13.12 Roche
• 13.13 TANDEM Diabetes Care
• 13.14 Valeritas
• 13.15 West
• 13.16 Ypsomed Selfcare Solutions